

Review

Clinical review: Balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use

Thomas G Slama

Department of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana 46260, USA

Corresponding author: Thomas G Slama, slamaidi@aol.com

Published: 29 October 2008

This article is online at <http://ccforum.com/content/12/5/233>

© 2008 BioMed Central Ltd

Critical Care 2008, **12**:233 (doi:10.1186/cc6994)

Abstract

Antipseudomonal carbapenems have played a useful role in our antimicrobial armamentarium for 20 years. However, a review of their use during that period creates concern that their clinical effectiveness is critically dependent on attainment of an appropriate dosing range. Unfortunately, adequate carbapenem dosing is missed for many reasons, including benefit/risk misconceptions, a narrow therapeutic window for imipenem and meropenem (due to an increased rate of seizures at higher doses), increasingly resistant pathogens requiring higher doses than are typically given, and cost containment issues that may limit their use. To improve the use of carbapenems, several initiatives should be considered: increase awareness about appropriate treatment with carbapenems across hospital departments; determine optimal dosing regimens for settings where multidrug resistant organisms are more likely encountered; use of, or combination with, an alternative antimicrobial agent having more favorable pharmacokinetic, pharmacodynamic, or adverse event profile; and administer a newer carbapenem with lower propensity for resistance development (for example, reduced expression of efflux pumps or greater stability against carbapenemases).

Introduction

Antipseudomonal carbapenems have proven to be valuable in the treatment of serious Gram-negative and polymicrobial mixed aerobic and anaerobic infections. In their two-decade history, imipenem and meropenem have primarily been used to treat intractable, severe infections. Although relatively rare at present, microbial resistance to carbapenems has reached clinically important levels for several organisms, including *Pseudomonas aeruginosa*, *Acinetobacter* spp., *Klebsiella* spp., and *Escherichia coli*. Carbapenem resistance can have a devastating impact because these agents often act as the last line of defense against resistant organisms.

It is increasingly clear that the clinical efficacy of carbapenems, particularly imipenem and meropenem, is critically dependent on optimal dosing, especially in intensive care

units (ICUs), burn units, and extended care facilities where multiresistant organisms are frequently encountered. Empiric treatment to cover multiresistant pathogens may necessitate using regimens at the higher end of the dosage range; however, the use of such high doses may be problematic in practice. For imipenem, the dose-dependent risk of neurotoxicity and seizure adverse events has led to recommendations for caution in using high-dose regimens [1-4]. Similar concerns may apply to meropenem, which has also been associated with an increased seizure risk [3,5-7]. Higher doses of carbapenems generally come at higher acquisition costs, while use of lower doses may increase the risk of treatment failure. Furthermore, suboptimal dosing is a well known driver for the development of antibiotic resistance during antibiotic therapy [8]. Appropriate dosing therefore presents a serious therapeutic dilemma for clinicians who prescribe carbapenems as empiric treatment for seriously ill patients.

This article explores the clinical impact of the relationship between carbapenem dosing and adverse event risks, pharmacodynamic-based dosing, and costs. It focuses on imipenem, meropenem, and doripenem, as they are more commonly used as empiric treatments for seriously ill patients in settings such as the ICU [9]. Ertapenem has not been discussed in this context because its lack of activity against *P. aeruginosa* and *Acinetobacter* spp. typically precludes its consideration for such cases [9]. Finally, it offers solutions to address this growing public health concern.

Clinical roles of antipseudomonal carbapenems

An analysis of data from the National Nosocomial Infections Surveillance system between 1986 and 2003 examined trends in the epidemiology of Gram-negative infections in ICUs [10]. While overall percentages of Gram-negative infections in ICU-treated pneumonias, surgical site infections,

ESBL = extended spectrum β -lactamase; ICU = intensive care unit; MDR = multidrug resistant; MIC = minimum inhibitory concentration; T>MIC = time greater than minimum inhibitory concentration.

urinary tract infections, and bloodstream infections either remained similar or declined, significant increases were seen in infections caused by cephalosporin-resistant *E. coli* and *Klebsiella pneumoniae* (related to extended spectrum β -lactamase (ESBL)-producing strains), ceftazidime-resistant *P. aeruginosa*, imipenem-resistant *P. aeruginosa*, and isolates of *Acinetobacter* spp. resistant to amikacin, ceftazidime, or imipenem. The authors concluded that increase in the prevalence of multidrug resistance - usually defined as resistance to three or more of the antimicrobial agents antipseudomonal penicillins, antipseudomonal cephalosporins, fluoroquinolones, carbapenems, and the aminoglycosides [11,12] - may be the greatest concern for Gram-negative bacilli associated with hospital-acquired infections [10].

Antipseudomonal carbapenems - imipenem, meropenem and doripenem - have excellent activity against most strains of many bacterial species and are regarded as safe and generally well-tolerated. Because of their broad spectrum, the antipseudomonal carbapenems are often effective against organisms resistant to other antimicrobial agents and are frequently used as empiric therapy in the ICU for polymicrobial infections. Of note, these carbapenems are resistant to ESBLs, and so are of value in treating infections caused by ESBL-producing strains of Enterobacteriaceae. Antipseudomonal carbapenems are indicated for a variety of hospital-treated infections, including intra-abdominal, urinary tract, and skin and skin structure infections. They are prescribed by hospitalists, surgeons, intensivists, wound care specialists, and infectious disease physicians in ICUs, postoperative surgical units, burn units, and long-term care facilities. This use may not always adhere to manufacturer-specific dosage and prescribing practices aimed at minimizing the development of carbapenem resistance in an effective manner.

In addition to empiric use of carbapenems, the use of this class for surgical prophylaxis has been proposed. While a recent study found a single prophylactic dose of ertapenem superior to cefotetan in colorectal surgery [13], the use of carbapenems for surgical prophylaxis remains controversial [13-16], and in the absence of more evidence favoring carbapenems for surgical prophylaxis, they are not recommended for use in this setting.

Carbapenem dosing and seizure risk

Multiple studies have found that imipenem and meropenem are associated with a dose-related increase in the risk for seizure events [3,4,17-25]. The mechanism is not fully understood [3,26,27]. Table 1 summarizes the range of seizure rates reported with either imipenem or meropenem.

In the largest report on seizures during imipenem treatment, underlying central nervous system disorders were common among patients who experienced seizures [17]. In this study, seizures occurred in 1.5% (37/2,516) of patients, although only 0.24% (6/2,516) were considered to be imipenem-

related. A more recent study found no increase in seizure risk for patients treated with imipenem at a maximum dose of 2 mg/day [3].

The risk of seizures with meropenem is widely believed to be lower than with imipenem [26], but the evidence is not definitive [3,6]. During clinical investigations, the overall seizure rate in meropenem-treated patients was 0.7% (20/2,904) [28], similar to the rate of 0.8% found in non-meningitis patients treated with meropenem [29]. Doripenem does not appear to have proconvulsive activity [30]. After more than a year in clinical use, there are no reports of doripenem-related seizures.

Although imipenem- or meropenem-related seizures are usually reversible on discontinuation and are manageable with anticonvulsants, the risk has made clinicians cautious about using these drugs at high doses, and this caution may be associated with the setting of upper limits on the dosing window for these carbapenems that are sub-therapeutic.

Carbapenem dosing and pharmacodynamic considerations

Imipenem, meropenem, and doripenem have elimination half-lives of approximately 1 hour [1,28,31]. Like other β -lactams, carbapenems have time-dependent bactericidal activity that results from avid binding to penicillin-binding proteins and disruption of bacterial cell wall synthesis. Carbapenems are highly resistant to most β -lactamases, including ESBLs [32]. The key pharmacodynamic parameter is the time during which the carbapenem concentration exceeds the minimum inhibitory concentration ($T > MIC$), which should be at least 20% of the dosing interval for bacteriostatic effect and 40% for maximum killing effect [33,34].

Dosing of carbapenems in the clinical setting must be carefully judged to give the best chance of meeting or exceeding the pharmacodynamic bactericidal $T > MIC$ target of 40%. Critical factors to take into account must include the severity of infection, patient-specific pharmacokinetic considerations and their impact on the drug concentration curve over time, and an assessment of the most likely causative pathogens. As carbapenems are often given empirically, judgments on this last point should be made based on local experience and on local antibiogram trends. When dealing with seriously ill patients, the possible presence of *P. aeruginosa* or *Acinetobacter* spp. should be considered, in addition to resistant strains of Enterobacteriaceae (for example, ESBL-producing strains). The potentially higher MIC values associated with these species or strains will be a factor in carbapenem selection and in the appropriate dosing of the chosen carbapenem to ensure achievement of the $T > MIC$ target for these difficult-to-treat organisms [35]. Ideally, to help prevent the risk of under- or overdosing, clinicians who can obtain carbapenem serum levels may consider doing so in ICU patients.

Table 1**Summary of selected reports of seizure adverse events in patients receiving imipenem or meropenem**

Study	Patient population	Dosage	Seizure incidence	Notes
Imipenem				
Winston <i>et al.</i> 1984 [24]	35 patients with infections from imipenem-susceptible organisms	4 g/day (23 patients); <4 g/day (12 patients)	None	
Calandra <i>et al.</i> 1985 [17]	First 2,516 patients treated; most had significant background disorders	<2 g/day, 32 percent; 2 g/day, 44 percent; >2 g/day, 24 percent	1.5 percent (37/2,516) all episodes; 0.24 percent (6/2,516) imipenem related	High rates of central nervous system disorders in patients with seizures
Winston <i>et al.</i> 1988 [25]	29 febrile granulocytopenic patients	1 g q6h	10.3 percent (3/29)	Versus 0 percent (0/58) treated with 2 β -lactams
Eng <i>et al.</i> 1989 [4]	First 22 patients treated	Varied (500 mg q12h to 1 g q6h)	22.7 percent (5/22)	
Rolston <i>et al.</i> 1992 [22]	371 febrile neutropenic cancer patients	12.5 mg/kg q6h	1.5 percent (3/196) imipenem + vancomycin; 3.4 percent (6/175) imipenem + amikacin	1 g qh6 for an 80 kg patient
Norrby <i>et al.</i> 1993 [19]	197 patients with severe nosocomial infections	500 mg q6h adjusted for renal dysfunction	0.5 percent (1/197)	Versus 0 percent (0/196) treated with ceftazidime
Raad <i>et al.</i> 1996 [21]	198 febrile neutropenic cancer patients	500 mg q6h	0.5 percent (1/198) imipenem + vancomycin	Versus 0 percent (0/192) treated with aztreonam + vancomycin
Karadeniz <i>et al.</i> 2000 [18]	82 pediatric patients with malignancies	50 mg/kg/day in 3 doses	3.6 percent (3/82)	
Koppel <i>et al.</i> 2001 [3]	98 patients	Max. 2 g/day	4.0/1,000 patient-days (on imipenem); 3.9/1,000 patient-days (not on imipenem)	No increase in risk due to imipenem
Winston <i>et al.</i> 2001 [94]	541 febrile granulocytopenic patients	500 mg q6h	2 percent	0 percent for clinafloxacin (200 mg every 12 h); $P = 0.06$
Meropenem				
Sieger <i>et al.</i> 1997 [96]	104 patients with nosocomial lower respiratory tract infections	1 g q8h	2.9 percent (3/104) all episodes; 0 percent meropenem related	
Norrby <i>et al.</i> 1999 [29]	4,872 patients in multiple trials	0.5 to 1 g q8h	Meropenem related: 0.08 percent (patients without meningitis); 0 percent (patients with meningitis)	

Carbapenem dosing and efficacy

Carbapenems such as imipenem and meropenem have a relatively narrow therapeutic window. The upper limit of this window is bounded by the dose-dependent risk of seizure adverse events, while the lower limit is set by pharmacodynamics. Carbapenems require a $T > MIC$ of at least 40% of their dosing interval for maximal bactericidal activity, and attainment of this pharmacodynamic target depends on dosage, individual patient pharmacokinetics, and the MIC of the target pathogen.

Several studies suggest that low doses of some carbapenems are associated with decreased efficacy as reflected in failure of cure, relapse, and superinfections, especially

when the infection involves species with high levels of resistance (for example, high percentage of pseudomonal isolates with MICs >4), such as *P. aeruginosa*. In patients with soft tissue infections, a 2 g/day regimen of imipenem provided a response rate of 95% (56% clinical cure, 38% improvement). Rates of microbiologic eradication ranged from 61% for *P. aeruginosa* to 100% for anaerobic bacteria [36]. In patients with febrile neutropenia, a study using the 2 g/day imipenem regimen reported a 77% response rate [37]. In patients with intra-abdominal infections, reported cure rates at the 2 g/day dosage range from 76% to 81% [38-40], and at a lower dosage (1.5 g/day in three 500-mg infusions 8 hours apart), the cure rate was 69% [41]. In the absence of controlled trials comparing different imipenem doses, these

Table 2

Probability of meropenem and imipenem attaining pharmacodynamic targets over entire dosing interval for 30, 50, and 100 percent T>MIC for selected bacterial populations [42]

Species	Pharmacodynamic target for entire dosing interval					
	30 percent T>MIC		50 percent T>MIC		100 percent T>MIC	
	Meropenem	Imipenem	Meropenem	Imipenem	Meropenem	Imipenem
<i>Escherichia coli</i>	100	100	100	100	100	94
<i>Klebsiella pneumoniae</i>	100	100	99	100	99	91
<i>Enterobacter cloacae</i>	100	100	100	100	95	71
<i>Serratia marcescens</i>	99	99	99	99	97	57
<i>Acinetobacter baumannii</i>	83	89	79	88	31	60
<i>Pseudomonas aeruginosa</i>	93	92	87	87	47	27

T>MIC, time greater than minimum inhibitory concentration.


data suggest that imipenem 2 g/day, which minimizes the incidence of seizure adverse events, may be less effective than 4 g/day. Thus, the need for a relatively low dose of imipenem to avoid seizure adverse events may offset its potential antimicrobial activity [4].

Kuti and colleagues [42] performed a Monte Carlo analysis to evaluate the probability of a 500 mg/6 hour dosing regimen of meropenem and imipenem to attain three different pharmacodynamic targets over the entire dosing interval (T>MIC 30%, T>MIC 50%, and T>MIC 100%) for different pathogens. Probabilities of staying above the MIC target throughout the dosing interval were similar between the two agents for T>MIC 30% or T>MIC 50% (Table 2). Figure 1 shows the probability of attaining the dosing targets across a range of MIC values, and while the differences are statistically significant, this calculation does not take into account protein binding differences that affect drug availability, reducing the accuracy of the findings, so the clinical significance is not clear [42]. Nevertheless, the model demonstrates the importance and complexities involved in delivering drugs effectively, taking into account pharmacodynamic properties.

Carbapenem resistance

Levels of resistance have increased considerably since the introduction of the first carbapenem, particularly among Gram-negative organisms [43]. Carbapenem resistance among *A. baumannii* and *P. aeruginosa* is a pressing problem [2,24,44-55] with steady increases in the prevalence and geographic spread of carbapenem-resistant strains [56-58], and reported rates of resistance as high as 16.3% worldwide. In North America, rates of 3.1% for *P. aeruginosa* [59] and 3.2% for *Acinetobacter* spp. [60] have been reported. Between 1997 and 1999 and 2004 and 2006, imipenem nonsusceptibility in *P. aeruginosa* increased from 23.6% to 29.3% and from 33.3% to 47.5% in *Acinetobacter* spp. [43]. Resistance in *K. pneumoniae* has also been reported [61].

Figure 1



Probability of attaining pharmacodynamic target during entire dosing interval (T>MIC >30%, 50%, and 100%) as a function of MIC for imipenem and meropenem at a dosage of 500 mg q6h. The 30% and 50% targets represent conservative estimates for bacteriostatic and bactericidal activity, respectively. Each curve shows the likelihood of the drug to stay above the target MIC for the entire dosing period based on the pathogen's MIC. Note the steep declines in probabilities for MIC values between 0.5 and 4. Reproduced with permission from Kuti et al. [42].

For 2004 and 2005, meropenem nonsusceptibility for *P. aeruginosa* was 9.7% and 12.4%, respectively, and for *Acinetobacter* spp. was 23.9% and 14.4%, respectively [62].

Three mechanisms for carbapenem resistance development have been identified: reduced carbapenem influx due to changes in expression of outer membrane porins [63],

secretion of carbapenemases [44,61,63,64], and efflux pump production [65]. Studies have suggested that resistance to imipenem may occur through a loss of porin expression alone, whereas with meropenem and doripenem the combination of porin loss together with increased efflux pump production is required to confer resistance [66-68].

Carbapenemases affect all three antipseudomonal carbapenems. At present they are relatively rare in the US; however, carbapenemases are a source for future concern as they inactivate not just carbapenems but virtually all β -lactam based antibacterials. Furthermore, detection of carbapenemases is not well-addressed by current automated testing systems. One study found that clinical laboratory testing misidentified approximately 15% of carbapenemase-producing *K. pneumoniae* strains as imipenem-susceptible [69]. A second study evaluated several automated test systems for detection of carbapenem resistance in 15 strains previously identified by broth microdilution as non-susceptible to imipenem and meropenem [70]. Depending on the test system used, between 1 and 13 of the 15 nonsusceptible strains were misidentified as susceptible. Although several methods for assessing carbapenemase production have been proposed [71-74], current guidelines do not include protocols for assaying carbapenemase production.


Imipenem and other carbapenems are considered the most effective available agents for treating *Acinetobacter* infections [75,76]. However, *A. baumannii* strains with high-level carbapenem resistance have become widespread [44]. Carbapenem-resistant *A. baumannii* has been reported worldwide, with outbreaks in the United States [51], Europe [45,49,54], South America [47], and Asia [50,53]. A recent Turkish study of patients with postneurosurgical meningitis found that 45% of 29 infections due to *Acinetobacter* spp. were imipenem-resistant before the initiation of therapy [52].

Carbapenem dosing and resistance

Resistance to carbapenems probably reflects two major drivers: the 20-year history of widespread use of imipenem and other carbapenems, and dosing that is suboptimal for pathogens with higher MICs, including intermediate and resistant organisms.

The general association between antibiotic use and antibiotic resistance is well known and believed to be causal [77]. Several reports exemplify this linkage for carbapenems. A study in a 600-bed community hospital found a strong association between imipenem usage and resistance in *P. aeruginosa* (Figure 2), although it is unclear whether the strain was treated adequately or if infection control techniques were uniformly adopted [78]. In another study, an attempt to prevent cephalosporin resistance by decreasing cephalosporin use caused a compensatory 140.6% increase in carbapenem use and an increase of 68.7% in the prevalence of imipenem-resistant *P. aeruginosa* infections [79].

Figure 2




Correlation between imipenem usage and imipenem resistance in *P. aeruginosa* in a community hospital. DDD, defined daily dose. Reproduced with permission from [78].

Similarly, a Polish pediatric hospital in which carbapenem use quadrupled between 1993 and 2002 found that the percentage of isolates susceptible to imipenem decreased from 95.7% to 81.7%, and that MIC₉₀ increased from 2 mg/dL to 16 mg/dL over the same period (Figure 3) [80].

Suboptimal dosing is a well known driver for the development of antibiotic resistance during antibiotic therapy [8]. As already noted, optimal bactericidal dosing for carbapenems requires maintaining drug levels so that T>MIC exceeds 40% of the dosing interval [26,81,82]. The standard 500 mg q6h regimen for imipenem/cilastatin meets this criterion in healthy individuals for susceptible pathogens. However, as shown in Figure 4, the 500 mg q6h regimen provides T>MIC values of 38% and 23%, respectively, for organisms with 1.5 to 3.0 mg/dL and 3 to 6 mg/dL MIC values [83]. Thus, the 500 mg q6h regimen and lower dosages may not be adequate for pathogens with a MIC >1.5 mg/dL.

Also of concern is the emergence of resistance during a course of carbapenem therapy. Fink and colleagues [48] investigated imipenem 3 g/day (1,000 mg q8h) in 200 patients with severe pneumonia. Microbiologic eradication occurred in 59% of the imipenem-treated patients. A total of 44 different strains of *P. aeruginosa* were isolated from 32 of these patients, and 50% of these strains developed imipenem resistance during the trial. More recently, in a study of nosocomial pneumonia, resistance developed in 33% (nine of 27) of patients with *P. aeruginosa* infections during treatment with imipenem 500 mg q6h. Resistance was present at the start of therapy in 5 of 32 (16%) patients (5 patients in this group were excluded after randomization) [55]. Use of

Figure 3



	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
No. of Isolates	210	216	258	231	269	232	281	259	277	252
Susceptible (%)	95.7	97.7	93.4	91.8	90	91.8	83.6	74.1	73.6	81.7
MIC ₉₀	2	4	4	4	4	4	16	16	16	16


Imipenem susceptibility and carbapenem use at a Polish pediatric hospital (1993 to 2002). DDD, defined daily dose. Reprinted from Patzer and Dzierzanowska [80], with permission from Elsevier.

imipenem as monotherapy to treat *P. aeruginosa* is not recommended because, as the examples above show, imipenem monotherapy is associated with considerable risk for *P. aeruginosa* resistance [84,85].

Intermediate susceptibility to imipenem is common among *P. aeruginosa* strains, and imipenem 500 mg q6h is frequently unable to achieve a sufficient T>MIC for effective eradication. In a trial comparing imipenem/cilastatin with ceftazidime for serious nosocomial infections, *P. aeruginosa* infections resolved in only 8 of 19 patients treated with imipenem, compared with 14 of 17 infections in patients treated with ceftazidime ($P=0.004$); resistance developed in 6 of 19 and 1 of 17 patients, respectively [19].

Altered carbapenem T>MIC values in an individual patient may also reflect the presence of severe illness, which can affect any pharmacokinetic parameter of a drug [81,86]. Regimens that do not account for these conditions may not maintain antibiotic levels sufficient for eradication [86]. One example is patients who are anuric or receiving continuous renal replacement therapy. Current continuous renal replacement therapy techniques provide rapid systemic drug clearance, and carbapenem regimens that are not adjusted

Figure 4



Effect of imipenem dose on the time during which serum imipenem exceeds the MIC₉₀ in healthy volunteers after a 30 minute infusion [83]. The dashed line shows the percentage of the dosing cycle required for optimum dosing.

accordingly may result in suboptimal drug levels, ineffective eradication, and an increased likelihood of resistance [81].

Overall, these considerations suggest that standard carbapenem dosages (for example, imipenem 2 g/day) may be suboptimal in terms of microbiologic eradication and resistance development for some infections in some patients, particularly pathogens with intermediate susceptibility and patients with altered pharmacokinetic properties when doses are not adjusted appropriately.

Clinical implications

The increasing prevalence of carbapenem resistance has broad and significant clinical implications because mortality and the cost of care are significantly increased in patients with carbapenem-resistant infections. Mortality in patients with carbapenem-resistant infections is approximately twice that of patients with carbapenem-susceptible infections: Kwon and colleagues [87] reported mortality rates of 57% and 27.5%, respectively, in patients with imipenem-resistant and imipenem-susceptible *Acinetobacter* bacteremia (relative risk 30-day mortality was 2.019 (95% confidence interval, 1.18 to 3.69; $P=0.007$). The primary risk factor for mortality was the use of discordant antimicrobial therapy, that is, when the pathogen was not susceptible to any agent in the antimicrobial regimen [87]. Studies of multidrug-resistant (MDR) *P. aeruginosa* infections report an odds ratio for mortality of 15.13 (95% confidence interval, 1.90 to 323.13; $P=0.001$) for MDR versus susceptible infections in patients with *P. aeruginosa* bacteremia [88], and hospital costs for MDR and susceptible infections of \$54,081 and \$22,116, respectively [89].

In addition, resistance can be transmitted and consequently lead to outbreaks of carbapenem-resistant infections.

Mikolajczyk and colleagues [90] estimated that 45% of imipenem-resistant *P. aeruginosa* infections result from transmission. Multiple outbreaks of carbapenem-resistant *A. baumannii* and *P. aeruginosa* have been reported, including a major citywide outbreak that occurred in 15 Brooklyn, NY hospitals in 1999. During the outbreak, carbapenem resistance was found in 53% of *A. baumannii* isolates and 24% of *P. aeruginosa* isolates. Approximately 400 patients were infected or colonized with a carbapenem-resistant strain [91]. Multidrug-resistant *A. baumannii* and *P. aeruginosa* are now endemic in the New York area, and the production of carbapenemases is increasingly common in *K. pneumoniae* and *E. coli* [56,58,69].

The increasing prevalence of imipenem resistance may also affect dosing requirements. In the past, before the emergence of MDR organisms became a common problem, the clinical impact of regimens using low imipenem dosages was relatively minor. With the emergence of MDR *P. aeruginosa* and *Acinetobacter* spp., inadequate dosing is increasingly likely to affect outcomes.

Although it is possible to prevent and control these outbreaks using a variety of measures such as patient screening and isolation, resistance monitoring, and infection control procedures, it is prudent to take measures to prevent or slow the development of carbapenem resistance.

Possible approaches to managing the problem include the use of novel dosing regimens, including extended infusions [92-94] and the use of novel or alternative antibiotic agents. Regimens using longer infusion times may help ensure that drug levels are maintained above the MIC₉₀ for at least 40% of the dosing interval. Alternative antibiotic agents could include novel agents, carbapenems or other agents, and combination therapies. Alternative agents can be evaluated by the criteria put forth by the Council for Appropriate and Rational Antibiotic Therapy (CARAT). These criteria include the strength of evidence supporting the use of the antibiotic, the expected therapeutic benefits and the possibility of resistance, the adverse-event profile, the cost-effectiveness of therapy with the agent, and the appropriate dosage and duration [95]. Cost-containment strategies may have to be adjusted to maintain adequate carbapenem dosing. Greater awareness and education regarding MDR pathogens and carbapenem treatment issues across hospital departments remains a vital need.

Conclusion

Imipenem and meropenem have been a useful part of the antimicrobial armamentarium for 20 and 10 years, respectively, and continue as valuable agents for treatment of Gram-negative infections. However, they have a narrow therapeutic window and the need for low-dose therapy to avoid neurotoxicity and the need for high-dose therapy to ensure efficacy and prevent the development of resistance are in

constant conflict. It is not yet clear whether an optimal antimicrobial dosage is attainable, given the seizure risk, or a suboptimal dosage acceptable, given the risks for treatment failure and resistance development. While avoidance of seizure adverse events may limit dosages - for example, imipenem 2 g/day or less (adjusted as necessary for renal dysfunction and other conditions) - these dosages are likely to be suboptimal for treatment of infections involving *P. aeruginosa*, *A. baumannii*, and other organisms with intermediate susceptibility. Underdosing may well decrease the efficacy of therapy while increasing the probability of resistance development.

Solutions include increasing awareness of treating resistant organisms, utilizing optimal dosing regimens in areas of the hospital where multiresistant organisms are more likely encountered, using alternative antimicrobials with more favorable pharmacokinetics, pharmacodynamics, and adverse-event profiles, and using newer carbapenems with lower propensity for resistance development (for example, reduced expression of efflux pumps or greater stability against carbapenemases). Achieving success requires hospital systems and physicians to continue to work together to create clinical solutions that optimize patient care.

Competing interests

TGS has been a consultant for Ortho-McNeil®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and is a member of the Speakers' Bureau for Pfizer, Inc. and Ortho-McNeil®. TGS has not received research funding.

Acknowledgments

The author would like to acknowledge Ben Caref, PhD (The Falk Group, LLC, New York, NY), who provided medical writing and editorial assistance. Ortho-McNeil® provided financial support for this assistance.

References

1. *Primaxin IV (imipenem and cilastatin for injection)* [Package Insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006.
2. Calandra GB, Ricci FM, Wang C, Brown KR: **The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials.** *J Clin Pharmacol* 1988, **28**:120-127.
3. Koppel BS, Hauser WA, Politis C, van DD, Daras M: **Seizures in the critically ill: the role of imipenem.** *Epilepsia* 2001, **42**:1590-1593.
4. Eng RH, Munsif AN, Yangco BG, Smith SM, Chmel H: **Seizure propensity with imipenem.** *Arch Intern Med* 1989, **149**:1881-1883.
5. Coves-Orts FJ, Borrás-Blasco J, Navarro-Ruiz A, Murcia-Lopez A, Palacios-Ortega F: **Acute seizures due to a probable interaction between valproic acid and meropenem.** *Ann Pharmacother* 2005, **39**:533-537.
6. Schranz J: **Comparisons of seizure incidence and adverse experiences between imipenem and meropenem.** *Crit Care Med* 1998, **26**:1464-1466.
7. Spriet I, Meersseman W, De TE, Wilmer A, Casteels M, Willems L: **Meropenem-valproic acid interaction in patients with cefepime-associated status epilepticus.** *Am J Health Syst Pharm* 2007, **64**:54-58.
8. Peterson LR: **Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance.** *Clin Microbiol Infect* 2005, **11**(Suppl 5):4-16.
9. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban

- DJ, Noreddin AM, Karlowsky JA: **Comparative review of the carbapenems.** *Drugs* 2007, **67**:1027-1052.
10. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System: **Overview of nosocomial infections caused by Gram-negative bacilli.** *Clin Infect Dis* 2005, **41**:848-854.
 11. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP, Sotto A: **Risk factors for multidrug-resistant *Pseudomonas aeruginosa* nosocomial infection.** *J Hosp Infect* 2004, **57**:209-216.
 12. Giske CG, Monnet DL, Cars O, Carmeli Y: **Clinical and economic impact of common multidrug-resistant Gram-negative bacilli.** *Antimicrob Agents Chemother* 2008, **52**:813-821.
 13. Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA: **Ertapenem versus cefotetan prophylaxis in elective colorectal surgery.** *N Engl J Med* 2006, **355**:2640-2651.
 14. Moine P, Asehnoune K: **Antibiotic prophylaxis in colorectal surgery.** *N Engl J Med* 2007, **356**:1684.
 15. Sexton DJ: **Carbapenems for surgical prophylaxis?** *N Engl J Med* 2006, **355**:2693-2695.
 16. Spiveack AR: **Antibiotic prophylaxis in colorectal surgery.** *N Engl J Med* 2007, **356**:1685.
 17. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA: **Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin.** *Am J Med* 1985, **78**:73-78.
 18. Karadeniz C, Oguz A, Canter B, Serdaroglu A: **Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.** *Pediatr Hematol Oncol* 2000, **17**:585-590.
 19. Norrby SR, Finch RG, Glauser M: **Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin.** European Study Group. *J Antimicrob Chemother* 1993, **31**:927-937.
 20. Norrby SR, Newell PA, Faulkner KL, Lesky W: **Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.** *J Antimicrob Chemother* 1995, **36**(Suppl A):207-223.
 21. Raad II, Whimbey EE, Rolston KV, Abi-Said D, Hachem RY, Pandya RG, Ghaddar HM, Karl CL, Bodey GP: **A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.** *Cancer* 1996, **77**:1386-1394.
 22. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L: **A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.** *Arch Intern Med* 1992, **152**:283-291.
 23. Sieger B, Berman SJ, Geckler RW, Farkas SA: **Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study.** Meropenem Lower Respiratory Infection Group. *Crit Care Med* 1997, **25**:1663-1670.
 24. Winston DJ, McGrattan MA, Busuttill RW: **Imipenem therapy of *Pseudomonas aeruginosa* and other serious bacterial infections.** *Antimicrob Agents Chemother* 1984, **26**:673-677.
 25. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE: **Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.** *Am J Med* 1988, **85**:21-30.
 26. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA: **Comparative pharmacokinetics of the carbapenems: clinical implications.** *Clin Pharmacokinet* 2000, **39**:185-201.
 27. Norrby SR: **Neurotoxicity of carbapenem antibacterials.** *Drug Saf* 1996, **15**:87-90.
 28. *Merrem IV (meropenem for injection)* [Package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2007.
 29. Norrby SR, Gildon KM: **Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.** *Scand J Infect Dis* 1999, **31**:3-10.
 30. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K: **Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.** *Toxicology* 2006, **222**:114-124.
 31. *Doribax (doripenem for injection)* [Package Insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2007.
 32. Petri WA: **Antimicrobial agents: penicillins, cephalosporins, and other β -lactam antibiotics.** In *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 10th edition. Edited by Goodman LS, Hardman JG, Limbird LE, Gilman AG. New York: McGraw-Hill; 2001:1189-1218.
 33. Craig WA: **Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.** *Clin Infect Dis* 1998, **26**:1-10.
 34. Drusano GL: **Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.** *Nat Rev Microbiol* 2004, **2**:289-300.
 35. Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM: **Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.** *Pharmacotherapy* 2008, **28**:691-698.
 36. Marier RL: **Role of imipenem/cilastatin in the treatment of soft tissue infections.** *Am J Med* 1985, **78**:140-144.
 37. Liang R, Yung R, Chiu E, Chau PY, Chan TK, Lam WK, Todd D: **Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.** *Antimicrob Agents Chemother* 1990, **34**:1336-1341.
 38. Barie PS, Vogel SB, Dellinger EP, Rotstein OD, Solomkin JS, Yang JY, Baumgartner TF: **A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections.** Cefepime Intra-abdominal Infection Study Group. *Arch Surg* 1997, **132**:1294-1302.
 39. Solomkin JS, Dellinger EP, Christou NV, Busuttill RW: **Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections.** *Ann Surg* 1990, **212**:581-591.
 40. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, Simms HH, Hill CS, Bjornson HS, Haverstock DC, Coulter HO, Echols RM: **Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections.** The Intra-Abdominal Infection Study Group. *Ann Surg* 1996, **223**:303-315.
 41. Brismar B, Malmberg AS, Tunevall G, Wretland B, Bergmann L, Mentzing LO, Nyström PO, Kihlström E, Backstrand B, Skau T, Kasholm-Tengue B, Sjöberg L, Ollson-Liljequist B, Tally FP, Gatenbeck L, Eklund AE, Nord CE: **Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.** *Antimicrob Agents Chemother* 1992, **36**:2766-2773.
 42. Kuti JL, Florea NR, Nightingale CH, Nicolau DP: **Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*.** *Pharmacotherapy* 2004, **24**:8-15.
 43. Fritsche TR, Sader HS, Strabala P, Jones RN: **Antibiotic susceptibility of respiratory bacterial isolates.** 2007:P 375.
 44. Brown S, Amyes S: **OXA (beta)-lactamases in *Acinetobacter*: the story so far.** *J Antimicrob Chemother* 2006, **57**:1-3.
 45. Bogaerts P, Naas T, Wybo I, Bauraing C, Soetens O, Piérard D, Nordmann P, Glupczynski Y: **Outbreak of infection by carbapenem-resistant *Acinetobacter baumannii* producing the carbapenemase OXA-58 in Belgium.** *J Clin Microbiol* 2006, **44**:4189-4192.
 46. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, Schaad U, Herter C, Eggimann P, Huber O, Ricou B, Suter P, Auckenthaler R, Chiolerio R, Bille J, Scheidegger C, Frei R, Glauser MP: **Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.** *Antimicrob Agents Chemother* 1994, **38**:1309-1313.
 47. Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo KL, Rea-Neto A, Penteado-Filho SR, Livermore DM, Woodford N: **Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in Curitiba, Brazil.** *J Clin Microbiol* 2003, **41**:3403-3406.
 48. Fink MP, Snyderman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RI, Haverstock DC, Reinhart HH, Echols RM: **Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin.** The Severe Pneumonia Study Group. *Antimicrob Agents Chemother* 1994, **38**:547-557.
 49. Heritier C, Dubouix A, Poirel L, Marty N, Nordmann P: **A nosocomial outbreak of *Acinetobacter baumannii* isolates expressing the carbapenem-hydrolyzing oxacillinase OXA-58.** *J Antimicrob Chemother* 2005, **55**:115-118.

50. Jeong SH, Bae IK, Park KO, An YJ, Sohn SG, Jang SJ, Sung KH, Yang KS, Lee K, Young D, Lee SH: **Outbreaks of imipenem-resistant *Acinetobacter baumannii* producing carbapenemases in Korea.** *J Microbiol* 2006, **44**:423-431.
51. Lolans K, Rice TW, Munoz-Price LS, Quinn JP: **Multicity outbreak of carbapenem-resistant *Acinetobacter baumannii* isolates producing the carbapenemase OXA-40.** *Antimicrob Agents Chemother* 2006, **50**:2941-2945.
52. Metan G, Alp E, Aygen B, Sumerkan B: **Carbapenem-resistant *Acinetobacter baumannii*: an emerging threat for patients with post-neurosurgical meningitis.** *Int J Antimicrob Agents* 2007, **29**:112-113.
53. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P: **Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia.** *J Clin Microbiol* 2005, **43**:4826-4829.
54. Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethmouti K, Maniatis AN, Legakis NJ, Tsakris A: **Outbreak of multiple clones of imipenem-resistant *Acinetobacter baumannii* isolates expressing OXA-58 carbapenemase in an intensive care unit.** *J Antimicrob Chemother* 2006, **57**:557-561.
55. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolerio R, Glauser MP, Cometta A: **Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.** *Cefepime Study Group. Antimicrob Agents Chemother* 2003, **47**:3442-3447.
56. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J: **Evolution of antimicrobial resistance among *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella pneumoniae* in Brooklyn, NY.** *J Antimicrob Chemother* 2007, **60**:78-82.
57. Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D, Quale J: **Detection and spread of *Escherichia coli* possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York.** *Clin Infect Dis* 2007, **44**:972-975.
58. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J: **Rapid spread of carbapenem-resistant *Klebsiella pneumoniae* in New York City: a new threat to our antibiotic armamentarium.** *Arch Intern Med* 2005, **165**:1430-1435.
59. Turner PJ: **Meropenem and imipenem activity against *Pseudomonas aeruginosa* isolates from the MYSTIC Program.** *Diagn Microbiol Infect Dis* 2006, **56**:341-344.
60. Rhomberg PR, Jones RN: **Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).** *Diagn Microbiol Infect Dis* 2007, **57**:207-215.
61. Kim SY, Park YJ, Yu JK, Kim HS, Park YS, Yoon JB, Yoo JY, Lee K: **Prevalence and mechanisms of decreased susceptibility to carbapenems in *Klebsiella pneumoniae* isolates.** *Diagn Microbiol Infect Dis* 2007, **57**:85-91.
62. Rhomberg PR, Jones RN: **Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).** *Diagn Microbiol Infect Dis* 2007, **57**:207-215.
63. Clark RB: **Imipenem resistance among *Acinetobacter baumannii*: association with reduced expression of a 33-36 kDa outer membrane protein.** *J Antimicrob Chemother* 1996, **38**:245-251.
64. Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA: **Resistance to imipenem in *Pseudomonas aeruginosa*: clinical experience and biochemical mechanisms.** *Rev Infect Dis* 1988, **10**:892-898.
65. Bornet C, Chollet R, Malléa M, Chevalier J, Davin-Regli A, Pagès JM, Bollet C: **Imipenem and expression of multidrug efflux pump in *Enterobacter aerogenes*.** *Biochem Biophys Res Commun* 2003, **301**:985-990.
66. Livermore DM, Oakton KJ, Carter MW, Warner M: **Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.** *Antimicrob Agents Chemother* 2001, **45**:2831-2837.
67. Mushtaq S, Ge Y, Livermore DM: **Doripenem versus *Pseudomonas aeruginosa* in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.** *Antimicrob Agents Chemother* 2004; **48**:3086-3092.
68. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y: **Potency of carbapenems for the prevention of carbapenem-resistant mutants of *Pseudomonas aeruginosa*: the high potency of a new carbapenem doripenem.** *J Antibiot (Tokyo)* 2006, **59**:220-228.
69. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, Karumudi U, Toloney P, Quale J: **Emergence of KPC-possessing *Klebsiella pneumoniae* in Brooklyn, New York: epidemiology and recommendations for detection.** *Antimicrob Agents Chemother* 2005, **49**:3018-3020.
70. Tenover FC, Kalsi RK, Williams PP, Stocker S, Lonsway D, Rasheed JK, Biddle JW, McGowan JE Jr, Hanna B: **Carbapenem resistance in *Klebsiella pneumoniae* not detected by automated susceptibility testing.** *Emerg Infect Dis* 2006, **12**:1209-1213.
71. Marchiaro P, Ballerini V, Spalding T, Cera G, Mussi MA, Morán-Barrio J, Vila AJ, Viale AM, Limansky AS: **A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers.** *J Antimicrob Chemother* 2008, **62**:336-344.
72. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, Carey RB, Thompson A, Stocker S, Limbago B, Patel JB: **Evaluation of methods to identify the *Klebsiella pneumoniae* carbapenemase in Enterobacteriaceae.** *J Clin Microbiol* 2007, **45**:2723-2725.
73. Soothill JS, Lock PE: **Screening for carbapenem-resistant bacteria.** *Lancet Infect Dis* 2005, **5**:597-598.
74. Parthasarathy P, Soothill J: **A new screening method for carbapenem-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*.** *J Hosp Infect* 2005, **61**:357-358.
75. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF: **Severe nosocomial infections with imipenem-resistant *Acinetobacter baumannii* treated with ampicillin/sulbactam.** *Int J Antimicrob Agents* 2003, **21**:58-62.
76. Russo TA: **Diseases caused by Gram-negative enteric bacilli.** In *Harrison's Principles of Internal Medicine*. 16th edition. Edited by Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. New York: McGraw-Hill; 2005:878-885.
77. Kollef MH, Fraser VJ: **Antibiotic resistance in the intensive care unit.** *Ann Intern Med* 2001, **134**:298-314.
78. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M: **Consumption of imipenem correlates with beta-lactam resistance in *Pseudomonas aeruginosa*.** *Antimicrob Agents Chemother* 2002, **46**:2920-2925.
79. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, Lim M: **Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial *Klebsiella*.** *JAMA* 1998, **280**:1233-1237.
80. Patzer JA, Dzierzanowska D: **Increase of imipenem resistance among *Pseudomonas aeruginosa* isolates from a Polish paediatric hospital (1993-2002).** *Int J Antimicrob Agents* 2007, **29**:153-158.
81. Fish DN, Teitelbaum I, Abraham E: **Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.** *Antimicrob Agents Chemother* 2005, **49**:2421-2428.
82. Turnidge JD: **The pharmacodynamics of beta-lactams.** *Clin Infect Dis* 1998, **27**:10-22.
83. Signs SA, Tan JS, Salstrom SJ, File TM: **Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration.** *Antimicrob Agents Chemother* 1992, **36**:1400-1403.
84. Alvan G, Nord CE: **Adverse effects of monobactams and carbapenems.** *Drug Saf* 1995, **12**:305-313.
85. Medical Letter. **Imipenem-cilastatin sodium (Primaxin).** *Med Lett Drugs Ther* 1986, **28**:29-31.
86. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T: **Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.** *J Antimicrob Chemother* 2007, **59**:277-284.
87. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY: **Impact of imipenem resistance on mortality in patients with *Acinetobacter bacteraemia*.** *J Antimicrob Chemother* 2007, **59**:525-530.

88. Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G, Cauda R: **Multidrug-resistant *Pseudomonas aeruginosa* bloodstream infections: analysis of trends in prevalence and epidemiology.** *Emerg Infect Dis* 2002, **8**:220-221.
89. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y: **Epidemiology and clinical outcomes of patients with multiresistant *Pseudomonas aeruginosa*.** *Clin Infect Dis* 1999, **28**:1128-1133.
90. Mikolajczyk RT, Sagel U, Bornemann R, Kramer A, Kretzschmar M: **A statistical method for estimating the proportion of cases resulting from cross-transmission of multi-resistant pathogens in an intensive care unit.** *J Hosp Infect* 2007, **65**:149-155.
91. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S: **Citywide clonal outbreak of multiresistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in Brooklyn, NY: the preantibiotic era has returned.** *Arch Intern Med* 2002, **162**:1515-1520.
92. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I: **Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.** *Crit Care Med* 2008, **36**:1089-1096.
93. Jaruratanasirikul S, Sriwiriyan S, Punyo J: **Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.** *Antimicrob Agents Chemother* 2005, **49**:1337-1339.
94. Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Guclalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ: **Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.** *Clin Infect Dis* 2001, **32**:381-390.
95. Slama TG, Amin A, Brunton SA, File TM Jr, Milkovich G, Rodvold KA, Sahm DF, Varon J, Weiland D Jr: **A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria.** *Am J Med* 2005, **118**(Suppl 7A):1S-6S.
96. Sieger B, Berman SJ, Geckler RW, Farkas SA: **Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study.** Meropenem Lower Respiratory Infection Group. *Crit Care Med* 1997; **25**:1663-1670.